[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100451684":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":44,"collaborators":7,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"SCF Pharma","INDUSTRY",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"OTHER","MAG-SPM treatment on isolated PBMC cells","Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.",{"type":10,"name":14,"description":12,"armGroupLabels":7,"otherNames":7},"Isolated PBMC cells without treatment.",[16],{"name":17,"affiliation":5,"role":18},"Samuel P Fortin, PhD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Samuel Fortin, PhD","CONTACT","418-750-8590","sfortin@scfpharma.com",{"name":26,"role":22,"phone":7,"phoneExt":7,"email":27},"Anne-Julie Landry, M.Sc","ajlandry@scfpharma.com",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Rimouski","Quebec","G0K 1P0","Canada","CA",{"type":37,"coordinates":38},"Point",[39,40],-68.52396,48.44879,{"lat":40,"lon":39},[43],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100451684","increased-inflammation-resolving-activity-by-omega-3-monoglycerides-in-peripheral-blood-mononuclear-cells-pbmc-100451684",false,"NCT05161702","Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).","PBMC","Inclusion Criteria:\n\n* Participant aged of at least 18 years old.\n\nExclusion Criteria:\n\n* Participant who use omega-3 supplements and \u002F or anti-inflammatory medication such as, but not limited to - Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren ) within 7 days of day 1 of the study.",true,"ALL","18 Years",{"count":57,"type":58},200,"ESTIMATED","OBSERVATIONAL","The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.",[62,63],"Resolution of Inflammation","Reduction of Cell Proliferation","2026-04-16",{"date":66,"type":67},"2026-04-17","ACTUAL",{"date":69,"type":67},"2019-03-12",{"date":71,"type":58},"2027-01-01",{"name":5,"class":6},1]